HOME >> MEDICINE >> NEWS
New prostate cancer treatment wins operations research award for Sloan-Kettering

The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.

Sloan-Kettering won the Franz Edelman Award for Achievement in Operations Research for work entitled "Operations Research Answers to Cancer Therapeutics." The work improves the survival rate of patients with prostate cancer, reduces the side effects of treatment, and reduces costs to the health care system.

Yesterday was the first time that the association awarded the Edelman prize for a medical treatment. The Sloan-Kettering win demonstrates how operations research and mathematics are increasingly bringing improvements to health care, not only in the areas of policy, finance, and public health but in diagnosis and treatment, as well.

Dr. Marco Zaider, Attending Physicist in Medical Physics at Memorial Sloan-Kettering Cancer Center received the award together with Professor Eva K. Lee, Director of the Center for Operations Research in Medicine and HealthCare in the School of Industrial and Systems Engineering at Georgia Institute of Technology.

The 2007 Franz Edelman Award winner was announced at a special awards banquet during The Institute for Operations Research and the Management Sciences (INFORMS) Conference on O.R. Practice in Vancouver. http://meetings.informs.org/Practice07/ The finalists included Coca-Cola Enterprises, Hewlett-Packard, DaimlerChrysler, and the U.S. Coast Guard.

Dr. Lee and Dr. Zaider devised sophisticated optimization modeling and computational techniques to implement an intra-operative 3D treatment planning system for brachytherapy (the placement of radioactive "seeds" inside a tumor) that offers a safer and more reliable treatment.

The real-time intra-operative planning system eli
'"/>

Contact: Barry List
barry.list@informs.org
443-794-5182
Institute for Operations Research and the Management Sciences
1-May-2007


Page: 1 2 3

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
3. African-American men understimate risk of prostate cancer
4. Treatment for early prostate cancer associated with type of specialist seen
5. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
6. Flaxseed stunts the growth of prostate tumors
7. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
8. Radium-223: An alternative treatment for prostate cancer
9. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
10. New prostate cancer clinical guidelines to be released
11. Data on new vaccine for prostate cancer to be presented

Post Your Comments:
(Date:5/23/2013)... 23, 2013 Today, Zane Benefits, Inc. ... . Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution plans and health ... common question from employees is “does my employer have ... not necessarily. The health care reform law, called the ...
(Date:5/23/2013)... 2013 Da Vinci surgical robot maker ... in Washington State May 23, according to Bloomberg.* The ... surgical robot lawsuits , expresses disappointment in the ruling ... to not read a single verdict as representative of ... Fred E. Taylor v. Intuitive Surgical Inc.; 09-2-03136-5, Superior ...
(Date:5/23/2013)... modified version of the polio virus might one ... Scientists at Duke Cancer Institute said the ... engineered form of the virus that is harmless ... therapy shows promise in the treatment of glioblastoma, ... said. "These early results are intriguing," principal ...
(Date:5/23/2013)... Ohio (May 23, 2013)Don,t doubt it when a woman ... time remembering things. A new study published online in ... Menopause Society (NAMS), helps confirm with objective tests that ... , In the past, some studies showed that hot ... Other studies showed that, even though there was a ...
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013 Amgen (NASDAQ: AMGN ... Annual  Healthcare Conference on Thursday, May 30, 2013, at the ... at 9:20 a.m. Eastern Daylight Time. Arvind Sood ... present at the conference. Live audio of the presentation can ... www.amgen.com , under Investors. A replay of the webcast will ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: